Brave Fight Against Cancer & Tumor

We are a bio-startup that aims to solve unmet medical needs for refractory tumors and rare diseases



CEO, Co-Founder

Born in 1990 in Okawa, Fukuoka, Japan. Complete Ph.D. course in Nagoya University Graduate School of Medicine in 2020. Research and develop “stromal targeting therapy for tumor”, and created and analyzed a prototype, which led to the founding of BFACT Co., Ltd.. Motto is “Anymore, we have to do something about unmet medical needs”. Pastime: Watching basketball and mixed martial arts (and sometimes listening to classical music).


Professor, Department of Tumor Pathology, Nagoya University School of Medicine. Has been engaged in basic research on transporters and intracellular scaffold proteins. Currently, Has been working on mesenchymal stem cells (MSCs) and cancer-associated fibroblast cells (CAFs).


Oct. 2022, Our founder, Professor Atsushi Enomoto of Nagoya University, has been selected for the “Innovative Research Project for Practical Application of Cancer Therapy” (3-1) by the Japan Agency for Medical Research and Development (AMED).https://www.amed.go.jp/koubo/15/01/1501C_00058.html

May. 2022, New Aichi Creative R&D Grant (Trial Type) was adopted. https://www.pref.aichi.jp/uploaded/attachment/420367.pdf

Apr. 2022, ESAKI CEO spoke on the radio program StartupN. https://startup-n.com/guest/archives/5816

Apr. 2022, Nikkan Kogyo Shimbun published an article about BFACT. https://newswitch.jp/p/31536

Jan. 2022, ESAKI CEO spoke at Kyoto University Innovation Capital Co., Ltd.’s event. https://www.kyoto-u.ac.jp/ja/event/2021-12-23

Nov. 2021, We received an award at the “GLOW Pitch” presentation event hosted by Nagoya city. https://nagoya-innovation.jp/news/2021/11/glow_pitch-.html

June. 2021, signed a license agreement with Tokai National Higher Education and Research System and Sowakai Shigei Medical Research Institute.

May. 2021, started a joint research project with the Tokai National Higher Education and Research System.

Dec. 2020, Third-party allotment of approximately 10M jpy to ANRI Inc. (Headquarters: Shibuya-ku, Tokyo) as a seed round.

Nov. 2020, BFACT Co., Ltd. was founded.


Headquarters: Nagono Campus, 14-1, Nakono 2-chome, Nishi-ku, Nagoya, Aichi, Japan. Post code: 451-0042

e-mail: info@bfact.co.jp